Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases?

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 9, 2012, Pages

  Marrack, Philippa ^a   Kappler, John W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIGEN; HLA DQ8 ANTIGEN; HLA DR2 ANTIGEN; HLA DR4 ANTIGEN; INSULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELIN BASIC PROTEIN; NEOANTIGEN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 2;

ALLELE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL MATURATION; GENETIC POLYMORPHISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN PROCESSING; THYMUS; GENETICS; IMMUNOLOGY; PROTEIN BINDING; REVIEW;

AUTOANTIGENS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; POLYMORPHISM, GENETIC; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; THYMUS GLAND;

EID: 84872352413     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a007765     Document Type: Article

References (90)

1. Abadie V, Sollid LM, Barreiro LB, Jabri B. 2011. Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annu Rev Immunol 29: 493-525.
2. Abiru N, Wegmann D, Kawasaki E, Gottlieb P, Simone E, Eisenbarth GS. 2000. Dual overlapping peptides recognized by insulin peptide B: 9-23 T cell receptor AV13S3 T cell clones of the NOD mouse. J Autoimmun 14: 231-237.
3. Anderton SM. 2004. Post-translational modifications of self antigens: Implications for autoimmunity. Curr Opin Immunol 16: 753-758.
4. Bankovich AJ, Girvin AT, Moesta AK, Garcia KC. 2004. Peptide register shifting within the MHC groove: Theory becomes reality. Mol Immunol 40: 1033-1039.
5. Burton AR, Vincent E, Arnold PY, Lennon GP, Smeltzer M, Li CS, Haskins K, Hutton J, Tisch RM, Sercarz EE, et al. 2008. On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes 57: 1321-1330.
6. Busch R, Rinderknecht CH, Roh S, Lee AW, Harding JJ, Burster T, Hornell TM, Mellins ED. 2005. Achieving stability through editing and chaperoning: Regulation of MHC class II peptide binding and expression. Immunol Rev 207: 242-260.
7. Chambers CA, Allison JP. 1997. Co-stimulation in T cell responses. Curr Opin Immunol 9: 396-404.
8. Cho SJ, Roman G, Yeboah F, Konishi Y. 2007. The road to advanced glycation end products: A mechanistic perspective. Curr Med Chem 14: 1653-1671.
9. Crawford F, Kozono H, White J, Marrack P, Kappler J. 1998. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 8: 675-682.
10. + T cells in type-1 diabetes in the NOD mouse. Proc Natl Acad Sci 108: 16729-16734.
11. Daniel D, Gill RG, Schloot N, Wegmann D. 1995. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 25: 1056-1062.
12. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. 1997. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7: 473-481.
13. Ehrhart M, Grube D, Bader MF, Aunis D, Gratzl M. 1986. Chromogranin A in the pancreatic islet: Cellular and subcellular distribution. J Histochem Cytochem 34: 1673-1682.
14. Erwig LP, Henson PM. 2008. Clearance of apoptotic cells by phagocytes. Cell Death Differ 15: 243-250.
15. Esposito C, Caputo I. 2005. Mammalian transglutaminases. Identification of substrates as a key to physiological function and physiopathological relevance. FEBS J 272: 615-631.
16. + T cell response to a rheumatoid arthritis-associated antigen. Arthritis Rheum 52: 1885-1896.
17. Feitsma AL, van der Voort EI, Franken KL, el Bannoudi H, Elferink BG, DrijfhoutJW, Huizinga TW, de Vries RR, Toes RE, Ioan-Facsinay A. 2010. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum 62: 117-125.
18. Feng D, Bond CJ, Ely LK, Maynard J, Garcia KC. 2007. Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex interaction "codon. " Nat Immunol 8: 975-983.
19. Gay D, Saunders T, Camper S, Weigert M. 1993. Receptor editing: An approach by autoreactive B cells to escape tolerance. J Exp Med 177: 999-1008.
20. Greenwald RJ, Freeman GJ, Sharpe AH. 2005. The B7 family revisited. Annu Rev Immunol 23: 515-548.
21. Hahn M, Nicholson MJ, Pyrdol J, Wucherpfennig KW. 2005. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat Immunol 6: 490-496.
22. Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, Valsasnini P, Nagy ZA, Sinigaglia F. 1995. Peptide binding specificity of HLA-DR4 molecules: Correlation with rheumatoid arthritis association. J Exp Med 181: 1847-1855.
23. Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC. 1991. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353: 765-769.
24. Haskins K, Portas M, Bradley B, Wegmann D, Lafferty K. 1988. T-lymphocyte clone specific for pancreatic islet antigen. Diabetes 37: 1444-1448.
25. Hattori M, Buse JB, Jackson RA, Glimcher L, Dorf ME, Minami M, Makino S, Moriwaki K, Kuzuya H, Imura H, et al. 1986. The NOD mouse: Recessive diabetogenic gene in the major histocompatibility complex. Science 231: 733-735.
26. He XL, Radu C, Sidney J, Sette A, Ward ES, Garcia KC. 2002. Structural snapshot of aberrant antigen presentation linked to autoimmunity: The immunodominant epitope of MBP complexed with I-Au. Immunity 17: 83-94.
27. Higashide T, Kawamura T, Nagata M, Kotani R, Kimura K, Hirose M, Inada H, Niihira S, Yamano T. 2006. T cell epitope mapping study with insulin overlapping peptides using ELISPOT assay in Japanese children and adolescents with type 1 diabetes. Pediatr Res 59: 445-450.
28. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, Lee DM, Hueber W, Robinson WH, Cairns E. 2008. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 205: 967-979.
29. Jensen PE, Weber DA, Thayer WP, Westerman LE, Dao CT. 1999. Peptide exchange in MHC molecules. Immunol Rev 172: 229-238.
30. Jones EY. 1997. MHC class I and class II structures. Curr Opin Immunol 9: 75-79.
31. Josefowicz SZ, Rudensky A. 2009. Control of regulatory T cell lineage commitment and maintenance. Immunity 30: 616-625.
32. Judkowski V, Pinilla C, Schroder K, Tucker L, Sarvetnick N, Wilson DB. 2001. Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2. 5 nonobese diabetic mice. J Immunol 166: 908-917.
33. Kappler JW, Roehm N, Marrack P. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49: 273-280.
34. Kent SC, Chen Y, Bregoli L, Clemmings SM, Kenyon NS, Ricordi C, Hering BJ, Hafler DA. 2005. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435: 224-228.
35. + thymocytes. Nature 333: 742-746.
36. Klein L, Jovanovic K. 2011. Regulatory T cell lineage commitment in the thymus. Semin Immunol 23: 401-409.
37. Kotzin BL, Falta MT, Crawford F, Rosloniec EF, Bill J, Marrack P, Kappler J. 2000. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci 97: 291-296.
38. Lee KH, Wucherpfennig KW, Wiley DC. 2001. Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2: 501-507.
39. Levisetti MG, Lewis DM, Suri A, Unanue ER. 2008. Weak proinsulin peptide-major histocompatibility complexes are targeted in autoimmune diabetes in mice. Diabetes 57: 1852-1860.
40. Lippolis JD, White FM, Marto JA, Luckey CJ, Bullock TN, Shabanowitz J, HuntDF, Engelhard VH. 2002. Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets. J Immunol 169: 5089-5097.
41. Mannering SI, Harrison LC, Williamson NA, Morris JS, Thearle DJ, Jensen KP, Kay TW, Rossjohn J, Falk BA, Nepom GT, et al. 2005. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med 202: 1191-1197.
42. Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW. 2008. Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol 26: 171-203.
43. Mathis D, Benoist C. 2007. A decade of AIRE. Nat Rev Immunol 7: 645-650.
44. Maynard J, Petersson K, Wilson DH, Adams EJ, Blondelle SE, Boulanger MJ, Wilson DB, Garcia KC. 2005. Structure of an autoimmune T cell receptor complexed with class II peptide-MHC: Insights into MHC bias and antigen specificity. Immunity 22: 81-92.
45. McFarland BJ, Beeson C. 2002. Binding interactions between peptides and proteins of the class II major histocompatibility complex. Med Res Rev 22: 168-203.
46. McGargill MA, Derbinski JM, Hogquist KA. 2000. Receptor editing in developing T cells. Nat Immunol 1: 336-341.
47. McKillop AM, Abdel-Wahab YH, Mooney MH, O'Harte FP, Flatt PR. 2002. Secretion of glycated insulin from pancreatic β-cells in diabetes represents a novel aspect of β-cell dysfunction and glucose toxicity. Diabetes Metab 28: 3S61-3S69.
48. Melino G, Piacentini M. 1998. "Tissue" transglutaminase in cell death: A downstream or a multifunctional upstream effector? FEBS Lett 430: 59-63.
49. Metzger TC, Anderson MS. 2011. Control of central and peripheral tolerance by Aire. Immunol Rev 241: 89-103.
50. Michels AW, Eisenbarth GS. 2010. Immunologic endocrine disorders. J Allergy Clin Immunol 125: S226-S237.
51. Mohan JF, Levisetti MG, Calderon B, Herzog JW, Petzold SJ, Unanue ER. 2010. Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat Immunol 11: 350-354.
52. Nagata M, Kotani R, Moriyama H, Yokono K, Roep BO, Peakman M. 2004. Detection of autoreactive T cells in type 1 diabetes using coded autoantigens and an immunoglobulin-free cytokine ELISPOT assay: Report from the fourth immunology of diabetes society T cell workshop. Ann NY Acad Sci 1037: 10-15.
53. Nakagawa TY, Rudensky AY. 1999. The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation. Immunol Rev 172: 121-129.
54. Negre-Salvayre A, Salvayre R, Auge N, Pamplona R, Portero-Otin M. 2009. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 11: 3071-3109.
55. Nicoloff G, Baydanoff S, Petrova C, Christova P. 2002. Antibodies to advanced glycation end products in children with diabetes mellitus. Vascul Pharmacol 39: 39-45.
56. Nikoopour E, Sandrock C, Huszarik K, Krougly O, Lee-Chan E, Masteller EL, Bluestone JA, Singh B. 2011. Cutting edge: Vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2. 5 T cells in nonobese diabetic mice. J Immunol 186: 3831-3835.
57. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, Bornkamm GW, Mautner J. 2003. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 33: 1250-1259.
58. O'Connor DT. 1983. Chromogranin: Widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul Pept 6: 263-280.
59. Patil NS, Hall FC, Drover S, Spurrell DR, Bos E, Cope AP, Sonderstrup G, MellinsED. 2001. Autoantigenic HCgp39 epitopes are presented by the HLA-DM-dependent presentation pathway in human B cells. J Immunol 166: 33-41.
60. Prochazka M, Leiter EH, Serreze DV, Coleman DL. 1987. Three recessive loci required for insulin-dependent diabetes in nonobese diabetic mice. Science 237: 286-289.
61. Qiao SW, Sollid LM, Blumberg RS. 2009. Antigen presentation in celiac disease. Curr Opin Immunol 21: 111-117.
62. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. 1999. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219.
63. Rudolph MG, Stanfield RL, Wilson IA. 2006. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 24: 419-466.
64. Sakaguchi S, ed. 2006. Regulatory T cells. Immunol Rev 212: 5-343.
65. Shalev I, Schmelzle M, Robson SC, Levy G. 2011. Making sense of regulatory T cell suppressive function. Semin Immunol 23: 282-292.
66. + T regulatory cell-mediated suppression. Immunity 30: 636-645.
67. Shiina T, Inoko H, Kulski JK. 2004. An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens 64: 631-649.
68. Shimonkevitz R, Colon S, Kappler JW, Marrack P, Grey HM. 1984. Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J Immunol 133: 2067-2074.
69. Sollid LM. 2000. Molecular basis of celiac disease. Annu Rev Immunol 18: 53-81.
70. Soros AA, Chalew SA, McCarter RJ, Shepard R, Hempe JM. 2010. Hemoglobin glycation index: A robust measure of hemoglobin A1c bias in pediatric type 1 diabetes patients. Pediatr Diabetes 11: 455-461.
71. Stadinski B, Kappler J, Eisenbarth GS. 2010a. Molecular targeting of islet autoantigens. Immunity 32: 446-456.
72. Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Piganelli JD, Barbour G, Bradley B, Crawford F, et al. 2010b. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 11: 225-231.
73. Stadinski BD, Zhang L, Crawford F, Marrack P, Eisenbarth GS, Kappler JW. 2010c. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci 107: 10978-10983.
74. Suri A, Vidavsky I, van der Drift K, Kanagawa O, Gross ML, Unanue ER. 2002. In APCs, the autologous peptides selected by the diabetogenic I-Ag7 molecule are unique and determined by the amino acid changes in the P9 pocket. J Immunol 168: 1235-1243.
75. Suri A, Walters JJ, Gross ML, Unanue ER. 2005. Natural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity. J Clin Invest 115: 2268-2276.
76. Suri A, Levisetti MG, Unanue ER. 2008. Do the peptide-binding properties of diabetogenic class II molecules explain autoreactivity? Curr Opin Immunol 20: 105-110.
77. Tivol EA, Schweitzer AN, Sharpe AH. 1996. Costimulation and autoimmunity. Curr Opin Immunol 8: 822-830.
78. Trombetta ES, Mellman I. 2005. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23: 975-1028.
79. Turk Z, Ljubic S, Turk N, Benko B. 2001. Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta 303: 105-115.
80. Valli A, Sette A, Kappos L, Oseroff C, Sidney J, Miescher G, Hochberger M, Albert ED, Adorini L. 1993. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 91: 616-628.
81. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. 2003. PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease. Bioessays 25: 1106-1118.
82. Walseng E, Bakke O, Roche PA. 2008. Major histocompatibility complex class II-peptide complexes internalize using a clathrin-and dynamin-independent endocytosis pathway. J Biol Chem 283: 14717-14727.
83. Winnock F, Christie MR, Batstra MR, Aanstoot HJ, Weets I, Decochez K, JopartP, Nicolaij D, Gorus FK. 2001. Autoantibodies to a 38-kDa glycosylated islet cell membrane-associated antigen in (pre)type 1 diabetes: Association with IA-2 and islet cell autoantibodies. Diabetes Care 24: 1181-1186.
84. Wirnsberger G, Hinterberger M, Klein L. 2011. Regulatory T-cell differentiation versus clonal deletion of autoreactive thymocytes. Immunol Cell Biol 89: 45-53.
85. Wucherpfennig KW. 2003. MHC-linked susceptibility to type 1 diabetes: A structural perspective. Ann NY Acad Sci 1005: 119-127.
86. Wucherpfennig KW, Call MJ, Deng L, Mariuzza R. 2009. Structural alterations in peptide-MHC recognition by self-reactive T cell receptors. Curr Opin Immunol 21: 590-595.
87. Yoshida K, Martin T, Yamamoto K, Dobbs C, Munz C, Kamikawaji N, Nakano N, Rammensee HG, Sasazuki T, Haskins K, et al. 2002. Evidence for shared recognition of a peptide ligand by a diverse panel of non-obese diabetic mice-derived, islet-specific, diabetogenic T cell clones. Int Immunol 14: 1439-1447.
88. Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB. 1986. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 324: 258-260.
89. Zhang L, Nakayama M, Eisenbarth GS. 2008. Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol 20: 111-118.
90. Zhou D, Blum JS. 2004. Presentation of cytosolic antigens via MHC class II molecules. Immunol Res 30: 279-290.